Your browser doesn't support javascript.
loading
Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure.
Markousis-Mavrogenis, George; Minich, Waldemar B; Al-Mubarak, Ali A; Anker, Stefan D; Cleland, John G F; Dickstein, Kenneth; Lang, Chim C; Ng, Leong L; Samani, Nilesh J; Zannad, Faiez; Metra, Marco; Seemann, Petra; Hoeg, Antonia; Lopez, Patricio; van Veldhuisen, Dirk J; de Boer, Rudolf A; Voors, Adriaan A; van der Meer, Peter; Schomburg, Lutz; Bomer, Nils.
Affiliation
  • Markousis-Mavrogenis G; Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
  • Minich WB; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany.
  • Al-Mubarak AA; ImmunometriX GmbH i.L, Brandenburgische Str. 83, D-10713 Berlin, Germany.
  • Anker SD; Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
  • Cleland JGF; Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Charitépl. 1, 10117 Berlin, Germany.
  • Dickstein K; Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK.
  • Lang CC; National Heart & Lung Institute, Imperial College, Guy Scadding Building, Dovehouse St, London SW3 6LY, UK.
  • Ng LL; University of Bergen, Stavanger University Hospital, Gerd-Ragna Bloch Thorsens gate 8, 4011 Stavanger, Norway.
  • Samani NJ; Division of Molecular & Clinical Medicine, University of Dundee, Nethergate, Dundee DD1 4HN, UK.
  • Zannad F; Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Groby Rd, Leicester LE3 9QP, UK.
  • Metra M; NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Groby Rd, Leicester LE3 9QP, UK.
  • Seemann P; University of Bergen, Stavanger University Hospital, Gerd-Ragna Bloch Thorsens gate 8, 4011 Stavanger, Norway.
  • Hoeg A; Université de Lorraine, Inserm CIC 1403, CHRU, Cité Universitaire, 57000 Metz, France.
  • Lopez P; Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza del Mercato, 15, 25121 Brescia BS, Italy.
  • van Veldhuisen DJ; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany.
  • de Boer RA; ImmunometriX GmbH i.L, Brandenburgische Str. 83, D-10713 Berlin, Germany.
  • Voors AA; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany.
  • van der Meer P; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany.
  • Schomburg L; ImmunometriX GmbH i.L, Brandenburgische Str. 83, D-10713 Berlin, Germany.
  • Bomer N; Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Cardiovasc Res ; 119(8): 1690-1705, 2023 07 06.
Article in En | MEDLINE | ID: mdl-36883593
ABSTRACT

AIMS:

The importance of autoantibodies (AABs) against adrenergic/muscarinic receptors in heart failure (HF) is not well-understood. We investigated the prevalence and clinical/prognostic associations of four AABs recognizing the M2-muscarinic receptor or the ß1-, ß2-, or ß3-adrenergic receptor in a large and well-characterized cohort of patients with HF. METHODS AND

RESULTS:

Serum samples from 2256 patients with HF from the BIOSTAT-CHF cohort and 299 healthy controls were analysed using newly established chemiluminescence immunoassays. The primary outcome was a composite of all-cause mortality and HF rehospitalization at 2-year follow-up, and each outcome was also separately investigated. Collectively, 382 (16.9%) patients and 37 (12.4%) controls were seropositive for ≥1 AAB (P = 0.045). Seropositivity occurred more frequently only for anti-M2 AABs (P = 0.025). Amongst patients with HF, seropositivity was associated with the presence of comorbidities (renal disease, chronic obstructive pulmonary disease, stroke, and atrial fibrillation) and with medication use. Only anti-ß1 AAB seropositivity was associated with the primary outcome [hazard ratio (95% confidence interval) 1.37 (1.04-1.81), P = 0.024] and HF rehospitalization [1.57 (1.13-2.19), P = 0.010] in univariable analyses but remained associated only with HF rehospitalization after multivariable adjustment for the BIOSTAT-CHF risk model [1.47 (1.05-2.07), P = 0.030]. Principal component analyses showed considerable overlap in B-lymphocyte activity between seropositive and seronegative patients, based on 31 circulating biomarkers related to B-lymphocyte function.

CONCLUSIONS:

AAB seropositivity was not strongly associated with adverse outcomes in HF and was mostly related to the presence of comorbidities and medication use. Only anti-ß1 AABs were independently associated with HF rehospitalization. The exact clinical value of AABs remains to be elucidated.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Heart Failure Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cardiovasc Res Year: 2023 Type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Heart Failure Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cardiovasc Res Year: 2023 Type: Article Affiliation country: Netherlands